Published March 2026 · 7 min read
Among the questions I am asked most often by newly diagnosed AuDHD adults — and by the GPs who refer them — the one I dread answering in a single sentence is: “Will stimulants work for me?” The honest answer is “probably, but not in the way you have read about online.” The 2025 clinical literature and the current Australian prescribing guidance both converge on a picture that is more cautious, more individualised, and ultimately more hopeful than either the “stimulants are magic” camp or the “stimulants are dangerous in autism” camp would have you believe.
What the evidence actually shows
Methylphenidate is still the only ADHD stimulant that has been formally trialled in autistic populations. The pooled data, summarised in the 2025 Carlat ADHD update and the 2025 Taylor & Francis review of ADHD-ASD clinical management, tell a consistent story: stimulants can reduce hyperactivity and inattention in autistic children and adults, but both the effect size and the tolerability are lower than in non-autistic ADHD populations. In some studies long-acting stimulants produced more side effects than immediate-release formulations, and the more severe the autistic presentation, the more of a problem those side effects tended to be.
The side-effect profile that turns up most often in AuDHD patients is not the one the textbooks warn about. It is irritability, emotional blunting, increased rigidity, interoceptive confusion (patients forget to eat or drink completely), and a sense that the person has become “flatter” even when the ADHD symptoms have improved. These are precisely the outcomes that matter most to the AuDHD community — and precisely the ones that get under-reported in trials designed around hyperactivity scales.
Start low, go slow, and listen harder than you normally would.
AADPA clinical guidance, 2025
What good Australian practice looks like in 2026
The Australian ADHD Professionals Association (AADPA) and Australian Prescriber both now recommend that stimulant initiation in patients with autism or another neurodevelopmental condition should begin at a lower dose than the standard titration schedule, move upward more slowly, and include explicit monitoring for the side effects that autistic patients are more likely to experience — and less likely to self-report.
Three features distinguish best practice from routine practice:
One — the prescriber treats “tolerability” as a two-person question. Because interoception is often impaired in AuDHD, the patient may not notice that they have stopped eating, stopped sleeping, or become emotionally flat. A trusted second observer — partner, family member, close friend — is not a nice-to-have. They are part of the safety net.
Two — the prescriber measures the right outcomes. “Did the ADHD symptoms go down?” is an incomplete question. The better battery includes: sleep, appetite, hydration, emotional range, sensory tolerance, meltdown frequency, and overall quality of life. In AuDHD, a drop in hyperactivity that comes at the cost of sensory overload is not a win.
Three — non-stimulant options are on the table from day one. Atomoxetine and guanfacine are slower-acting, less peaky, and in some AuDHD patients are better tolerated than stimulants. The 2025 Australian guidance treats them as legitimate first-line options in this population, not as second-best fallbacks.
The politics of the prescription
There is a second problem that the clinical literature is only starting to acknowledge: the ongoing Australian stimulant shortage. AADPA issued formal clinical guidance in June 2025 on managing the shortage, and the downstream effect on AuDHD patients has been disproportionate. Patients who were finally diagnosed after twenty years of being missed are now being told there is no reliable supply of the medication that might help. If you are in this position, the current guidance is clear: do not switch formulations without clinical input, do not ration on your own, and do ask your prescriber about non-stimulant options before you run out.
The bottom line
Stimulants are not magic, and they are not poison. They are one tool in a clinical picture that has finally started being taken seriously. For roughly half of AuDHD adults the medication will be part of the answer. For the other half, the answer will be somewhere else — non-stimulants, interoception work, environmental changes, or all three. The only clinical error the 2025 evidence clearly rules out is the one-size-fits-all script. AuDHD brains are not average ADHD brains, and the prescribing pad needs to catch up.
Further reading
Carlat Report (2025). ADHD Update 2025: New Treatments and Current Approaches for Co-Occurring Conditions.
AADPA (2025). ADHD Medication Shortage Clinical Guidance.
Australian Prescriber (2024). Pharmacological management of ADHD in children and adolescents.
Taylor & Francis (2025). An update on the comorbidity of ADHD and ASD and its clinical management.
Leave a Reply